R. Wada

发表

Modeling the Onset and Offset of Dental Pain Relief by Ibuprofen

S. Jayawardena, J. Mandema, P. Desjardins, 2012, Journal of clinical pharmacology.

Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.

J. Moberly, H. Kastrissios, S. Rohatagi, 2008, British journal of clinical pharmacology.

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Jin Y. Jin, G. Rossato, S. Girish, 2019, Journal of Immunotherapy for Cancer.

Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes

K. Winters, S. Rohatagi, D. Small, 2010, Journal of clinical pharmacology.

Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates

H. Erickson, J. Tibbitts, G. L. Lewis Phillips, 2014, Cancer Chemotherapy and Pharmacology.

Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer

Jin Y. Jin, N. Zhang, Michelle L. Green, 2016, Cancer Chemotherapy and Pharmacology.

Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials

T. Kerbusch, Petra M Jauslin, L. Wenning, 2020, British journal of clinical pharmacology.

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

M. Kågedal, C. Wynne, I. Nijem, 2018, Journal of clinical pharmacology.

Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma

J. Shah, Hongmei Xu, S. Shacham, 2021, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors

T. Garimella, F. LaCreta, K. Yoshihara, 2020, Clinical pharmacology and therapeutics.

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies

Hua Yang, B. Poland, Xuemin Jiang, 2021, Clinical and translational science.

Model-Based Meta-Analysis for Quantifying Paclitaxel Dose Response in Cancer Patients

H. Li, A. Joshi, D. Lu, 2014, CPT: pharmacometrics & systems pharmacology.

Modeling and simulation of orlistat to predict weight loss and weight maintenance in obesity patients.

T. Kawanishi, S. Iida, Y. Matsumoto, 2014, Drug metabolism and pharmacokinetics.

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

B. Lum, Chunze Li, D. Heinzmann, 2015, Cancer Chemotherapy and Pharmacology.

Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses

J. Baselga, H. Iwata, K. Tamura, 2019, Poster Session Abstracts.

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

H. Iwata, K. Tamura, J. Watanabe, 2021, Clinical pharmacology and therapeutics.

Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.

Katherine A. Winters, Lei Zhou, Ping Chen, 2012, Endocrinology.

Modeling and Simulation of Effects of Adherence, Pharmacokinetic, and Pharmacodynamic Characteristics in Development of Resistance to HIV Regimens in Treatment-Naive Patients

A. Hsu, B. Poland, E. Sun, 2004 .

Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

J. Dean, Hanbin Li, R. Wada, 2013 .

Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166.

A. Peterson, M. Stroh, J. Frye, 2020 .

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer

E. Cho, B. Poland, L. Musib, 2019, CPT: pharmacometrics & systems pharmacology.

Development of a Predictive Pharmacokinetic Model for a Novel Cyclooxygenase‐2 Inhibitor

J. Moberly, H. Kastrissios, S. Rohatagi, 2006, Journal of clinical pharmacology.

Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

S. Girish, Shang-Chiung Chen, A. Joshi, 2017, Cancer Chemotherapy and Pharmacology.

Exposure–efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC).

S. Swain, M. Untch, S. Girish, 2013 .

Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX‐2 Inhibitor

K. Yoshihara, J. Moberly, H. Kastrissios, 2007, Journal of clinical pharmacology.

Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making

S. Visser, Helen Zhou, Tai-Tsang Chen, 2023, CPT: pharmacometrics & systems pharmacology.